JEFFREY M. DAYNO, M.D.
Interim Chief Executive Officer and Chief Medical Officer
Jeffrey M. Dayno, M.D., is Interim Chief Executive Officer and Chief Medical Officer for Harmony Biosciences.
A nationally recognized expert in neuroscience and a leader at Harmony Biosciences since the company's inception, Dr. Dayno is responsible for leading the company's business growth and advancing the clinical development programs. He has been the driving force behind Harmony's patient-focused drug development model that uses patient insights to inform clinical research programs and a pipeline focused on potential, next-generation treatments to help people living with rare neurological diseases.
Dr. Dayno is a neurologist with 10 years of experience in clinical/academic medicine followed by 25 years of experience in leadership roles at Merck & Co., Cephalon, and ViroPharma, building and leading clinical, regulatory and medical affairs teams toward multiple NDA approvals and medical support of successful product launches.
Dr. Dayno earned his medical degree from Temple University School of Medicine, did his residency training in Neurology at Temple University Hospital, and completed a fellowship in Stroke and Cerebrovascular Disorders in the Department of Neurology at Henry Ford Hospital. He is a member of the Board of Visitors of the Lewis Katz School of Medicine at Temple University and serves on the Board of Advisors for Life Science Cares Philadelphia.
